Breaking: GW Pharma Confirms No Epidiolex Supply Issues

New Cannabis Ventures
By Alan Brochstein, CFAFeb 20, 2019, 3:18 pm354 pts
A post on Twitter today has pressured GW Pharma (NASDAQ: GWPH), which dipped more than 3% to $145.21. The post, by Ryan Flinn, a Bay Area journalist in healthcare public relations, indicated that he was having trouble procuring Epidiolex, recently approved for treating seizures caused by epilepsy: Seeking Alpha…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Report Predicts Global Psychedelic Drugs Market Will Reach $22.6B by 2033 77

Texas Lawmakers Will Continue Pursuing Hemp Product Restrictions In Second Special Session 77

Auxly reports soaring net income in Q2 2025 72

Brute’s Roots’ Celebrates 2-Year Anniversary! 71

New York cannabis ruling could have far-reaching implications 68

Thoughts on the NJ Adult-use Cannabis Market and the Feds 58

Weed could be the Republican party’s secret weapon 53

Klutch Cannabis Opening 5th Ohio Dispensary in Northfield 38

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.